MoonLake Immunotherapeutics(US:MLTX) Globenewswireยท2025-10-26 13:16Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of violations of federal securities laws, particularly concerning misleading statements about its product SLK compared to BIMZELX [4][6]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against MoonLake [4]. - Investors who suffered losses in MoonLake between March 10, 2024, and September 29, 2025, are encouraged to contact the firm to discuss their legal rights [1][9]. - The complaint alleges that MoonLake and its executives made false statements regarding the efficacy and clinical benefits of SLK compared to traditional monoclonal antibodies [6]. Group 2: Stock Performance and Market Reaction - Following the announcement of disappointing results from the Phase 3 VELA program on September 28, 2025, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [7]. - The results indicated that SLK did not demonstrate competitive efficacy relative to BIMZELX, leading to significant investor losses [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. - The firm has offices in New York, Pennsylvania, California, and Georgia, indicating a broad operational footprint [5].